# Which molecule the 2026 HHS policy calls TB-500

- Article ID: research-366
- Product: TB-500 (tb-500-450)
- Canonical page: https://heritagebiolabs.com/research-library/articles/366-which-molecule-the-2026-hhs-policy-calls-tb-500
- Product collection: https://heritagebiolabs.com/research-library/products/tb-500
- Product page: https://heritagebiolabs.com/product/tb-500-450
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains linked by peptide bonds. Small changes to the chain or its ends can alter how a peptide interacts with cells. In an October 2026 compounding policy, the U.S. Department of Health and Human Services defined TB-500 acetate as the acetate form of an N-acetylated seven-amino-acid fragment of thymosin beta-4. The policy makes the chemical identity explicit because names used for research products can be ambiguous. [1] [2]

The agency's notice describes interim enforcement discretion for certain bulk peptide substances under section 503A while the relevant list is developed through rulemaking. The accompanying policy specifies conditions for the compounders it addresses. They include testing the identity and quality of bulk material and reporting adverse events. A product within the policy's scope contains only one active ingredient from its list. [1] [2]

FDA briefing materials from July 2026 also distinguished the acetylated fragment from the complete thymosin beta-4 molecule. The agency evaluated TB-500 in the context of its nomination for wound healing. Evaluation of a nominated bulk substance for compounding and approval of a finished drug for a specific use are different regulatory decisions. The later HHS notice addresses enforcement under the stated conditions. It does not provide a clinical finding that the fragment heals wounds. [1] [2] [3]

The regulatory definition is useful for reading studies. An experiment that uses the specified sequence can be identified as research on the fragment. Studies of full-length thymosin beta-4 or of a preparation described only by a product name have different molecular evidence. The policy supplies a clear identity for the substance it covers, while study methods establish the identity of what was tested in each experiment. [2] [3]

## Sources

1. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register (publication 2026-10-30). <https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf>
2. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. U.S. Department of Health and Human Services (publication 2026-10). <https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf>
3. U.S. Food and Drug Administration. July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate). U.S. Food and Drug Administration (publication 2026-07). <https://www.fda.gov/media/193349/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 074 - TB-500 and Tesamorelin.docx; article 366; content SHA-256 6df2ccd7eb0b962be2a4a0ca219e2acac9ef669dae31fd078b9fea0aba75e5ee.
